English

BioStock: Curasight’s rights issue subscription period has commenced

Report this content

Curasight is currently conducting a DKK 100 million rights issue, with the subscription period closing on May 16. Having secured DKK 47 million in pre-subscriptions and guarantees, plus a DKK 18 million renegotiated loan facility, the company aims to advance in parallel its uTRACE diagnostic and uTREAT therapeutic platforms for cancers such as prostate cancer and glioblastoma.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/curasights-rights-issue-subscription-period-has-commenced/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Subscribe

Documents & Links

Quick facts

BioStock: Curasight’s rights issue subscription period has commenced
Tweet this

Quotes

We believe our theranostic approach using the uPAR target could provide improved diagnosis and more gentle treatment options for patients in the future. The rights issue will give us an important injection of capital that will enable us to pursue our updated strategy of developing uTRACE and uTREAT in parallel.
Ulrich Krasilnikoff, CEO Curasight